We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 10. | 장 마감 후 (AMC) | $-0.48 | — | — | $0 | — | 예정 |
Consensus PT $44.71 · 17 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 26. | Guggenheim | — | 의견 유지 | Buy → Buy | — | Guggenheim: Buy |
| 2026. 05. 23. | Truist Securities | — | 의견 유지 | Hold → Hold | — | Truist Securities: Hold |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
| # | 기관 | 운용 형태 | 보유 주식 | 평가액 | 비중 | 변화율 | 포지션 |
|---|---|---|---|---|---|---|---|
| 1 | Point72 Asset Management, L.P. | Point72 Asset Management, L.P. | 2,000,000 | $50.84B | 0.08% | — | 신규 편입 |
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Stored first · Google News · Yahoo Finance (English)
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
IMVT's Q4 loss wider than expected, stock up 35% on strong study data MSN
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 Moomoo
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
IMVT rockets 35% despite wider loss as arthritis drug shines in study MSN
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock - Moomoo
Immunovant(IMVT.US) Director Sells US$7.44 Million in Common Stock Moomoo
Immunovant Director Sold Shares Worth Over $7.4M - TradingView
Immunovant Director Sold Shares Worth Over $7.4M TradingView
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options - Stock Titan
Immunovant (IMVT) director Fromkin sells 221,951 shares after exercising options Stock Titan